The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review

References

• Siracusa R, Paola RD, Cuzzocrea S, et al. Fibromyalgia: pathogenesis, mechanisms, diagnosis and treatment options update. Int J Mol Sci. 2021;22(8):3891. doi:10.3390/ijms22083891
   PubMed Web of Science ®Google Scholar
• Sarzi-Puttini P, Giorgi V, Marotto D, et al. Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. Nat Rev Rheumatol. 2020;16(11):645–660. doi:10.1038/s41584-020-00506-w
   PubMed Web of Science ®Google Scholar
• CDC. Fibromyalgia. Arthritis types. Available from: https://www.cdc.gov/arthritis/types/fibromyalgia.htm. Accessed October 12, 2022.
   Google Scholar
• D’Onghia M, Ciaffi J, Ruscitti P, et al. The economic burden of fibromyalgia: a systematic literature review. In: Seminars in Arthritis and Rheumatism. Elsevier; 2022.
   Google Scholar
• Harte SE, Harris RE, Clauw DJ. The neurobiology of central sensitization. J Appl Biobehav Res. 2018;23(2):e12137. doi:10.1111/jabr.12137
   Web of Science ®Google Scholar
• Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: from pathophysiology to therapy. Nat Rev Rheumatol. 2011;7(9):518–527. doi:10.1038/nrrheum.2011.98
   PubMed Web of Science ®Google Scholar
• Clauw DJ, Arnold LM, McCarberg BH. The Science of Fibromyalgia. in Mayo Clinic Proceedings. Elsevier; 2011.
   Google Scholar
• Coskun Benlidayi I. Role of inflammation in the pathogenesis and treatment of fibromyalgia. Rheumatol Int. 2019;39(5):781–791. doi:10.1007/s00296-019-04251-6
   PubMed Web of Science ®Google Scholar
• Mastrangelo F, Frydas I, Ronconi G, et al. Low-grade chronic inflammation mediated by mast cells in fibromyalgia. J Biol Reg Homeos. 2018;32:195–198.
   PubMed Web of Science ®Google Scholar
• Kia S, Choy E. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines. 2017;5(2):20. doi:10.3390/biomedicines5020020
   PubMed Web of Science ®Google Scholar
• Bihari B. Bernard Bihari, MD: low-dose naltrexone for normalizing immune system function. Altern Ther Health Med. 2013;19(2):56–65.
   PubMedGoogle Scholar
• Schwaiger T. The uses of low-dose naltrexone in clinical practice. 2017.
   Google Scholar
• Swidan S. Low-dose naltrexone: immune and inflammatory mediator extraordinaire. In: Advanced Therapeutics in Pain Medicine. CRC Press; 2020:275–290.
   Google Scholar
• Hatfield E, Phillips K, Swidan S, et al. Use of low-dose naltrexone in the management of chronic pain conditions: a systematic review. J Am Dent Assoc. 2020;151(12):891–902.e1. doi:10.1016/j.adaj.2020.08.019
   PubMed Web of Science ®Google Scholar
• Kim PS, Fishman MA. Low-dose naltrexone for chronic pain: update and systemic review. Curr Pain Headache Rep. 2020;24(10):64. doi:10.1007/s11916-020-00898-0
   PubMed Web of Science ®Google Scholar
• Siembida J, Johnson B. Depression in fibromyalgia patients may require low-dose naltrexone to respond: a case report. Cureus. 2022;14(2):e22677. doi:10.7759/cureus.22677
   PubMedGoogle Scholar
• Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Med. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Panksepp J, Johnson B. Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option? Psychosomatics. 2012;53(6):591–594. doi:10.1016/j.psym.2011.11.006
   PubMed Web of Science ®Google Scholar
• Younger J, Noor N, McCue R, et al. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels. Arthritis Rheum. 2013;65(2):529–538. doi:10.1002/art.37734
   PubMed Web of Science ®Google Scholar
• Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):18. doi:10.3390/biomedicines5020016
   PubMed Web of Science ®Google Scholar
• Metyas S, Chen CL, Yeter K, et al. Low dose naltrexone in the treatment of fibromyalgia. Curr Rheumatol Rev. 2018;14(2):177–180. doi:10.2174/1573397113666170321120329
   PubMedGoogle Scholar
• Oaks Z, Stage A, Middleton B, et al. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone. Discov Med. 2018;26(144):197–206.
   PubMed Web of Science ®Google Scholar
• Bruun-Plesner K, Blichfeldt-Eckhardt MR, Vaegter HB, et al. Low-dose naltrexone for the treatment of fibromyalgia: investigation of dose-response relationships. Pain Med. 2020;21(10):2253–2261. doi:10.1093/pm/pnaa001
   PubMedGoogle Scholar
• Jackson D, Singh S, Zhang-James Y, et al. The effects of low dose naltrexone on opioid induced hyperalgesia and fibromyalgia. Front Psychiatry. 2021;12:136. doi:10.3389/fpsyt.2021.593842
   Google Scholar
• Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci. 2018;6(4):82. doi:10.3390/medsci6040082
   Google Scholar
• Wang D, Sun X, Sadee W. Different effects of opioid antagonists on μ-, δ-, and κ-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Therap. 2007;321(2):544–552. doi:10.1124/jpet.106.118810
   PubMedGoogle Scholar
• Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. doi:10.1007/s10067-014-2517-2
   PubMed Web of Science ®Google Scholar
• Watkins LR, Hutchinson MR, Ledeboer A, et al. Glia as the “bad guys”: implications for improving clinical pain control and the clinical utility of opioids. Brain Behav Immun. 2007;21(2):131–146. doi:10.1016/j.bbi.2006.10.011
   PubMed Web of Science ®Google Scholar
• Myers JS. Proinflammatory cytokines and sickness behavior: implications for depression and cancer-related symptoms. Oncol Nurs Soc. 1969;35(5):802–807.
   Google Scholar